KRP 105
Alternative Names: KRP105Latest Information Update: 20 Sep 2010
Price :
$50 *
At a glance
- Originator Kyorin Pharmaceutical
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 07 Nov 2006 Preclinical trials in Hyperlipidaemia in Japan (unspecified route)